Last reviewed · How we verify
RO7200220
At a glance
| Generic name | RO7200220 |
|---|---|
| Also known as | Vamikibart |
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Vamikibart in Participants With Uveitic Macular Edema (PHASE3)
- A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema (PHASE3)
- A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema (PHASE2)
- A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema (PHASE2)
- A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO7200220 CI brief — competitive landscape report
- RO7200220 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI